- Home
- VNDA vs RCS Comparison
VNDA vs RCS Comparison
Compare VNDA & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- RCS
- Stock Information
- Founded
- VNDA 2002
- RCS 1994
- Country
- VNDA United States
- RCS United States
- Employees
- VNDA N/A
- RCS N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- RCS Investment Managers
- Sector
- VNDA Health Care
- RCS Finance
- Exchange
- VNDA Nasdaq
- RCS Nasdaq
- Market Cap
- VNDA 270.2M
- RCS 279.8M
- IPO Year
- VNDA 2006
- RCS N/A
- Fundamental
- Price
- VNDA $4.73
- RCS $7.42
- Analyst Decision
- VNDA Buy
- RCS
- Analyst Count
- VNDA 1
- RCS 0
- Target Price
- VNDA $13.00
- RCS N/A
- AVG Volume (30 Days)
- VNDA 641.3K
- RCS 141.1K
- Earning Date
- VNDA 11-06-2024
- RCS 01-01-0001
- Dividend Yield
- VNDA N/A
- RCS 10.12%
- EPS Growth
- VNDA N/A
- RCS N/A
- EPS
- VNDA N/A
- RCS N/A
- Revenue
- VNDA $182,022,000.00
- RCS N/A
- Revenue This Year
- VNDA $6.70
- RCS N/A
- Revenue Next Year
- VNDA $51.03
- RCS N/A
- P/E Ratio
- VNDA N/A
- RCS N/A
- Revenue Growth
- VNDA N/A
- RCS N/A
- 52 Week Low
- VNDA $3.30
- RCS $4.51
- 52 Week High
- VNDA $6.75
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- VNDA 48.57
- RCS 41.52
- Support Level
- VNDA $4.68
- RCS $7.35
- Resistance Level
- VNDA $4.98
- RCS $7.75
- Average True Range (ATR)
- VNDA 0.18
- RCS 0.14
- MACD
- VNDA 0.05
- RCS -0.08
- Stochastic Oscillator
- VNDA 40.00
- RCS 3.61
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.